Tabalumab
As of the edition of 20 October 2026, Tabalumab is an antibody: stopped in 2015; acts on TNFSF13B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2015
- Kind
- Antibody
- Registered trials
- 21, 7 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Tabalumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFSF13B | Tumor necrosis factor ligand superfamily member 13B | Q9Y275 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 8 | 7 | 0 | 1 |
| Phase 3 | 9 | 3 | 0 | 6 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2006 to now |
| Applied Molecular Evolution | Lead sponsor of trials | 2008 to now |